BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a close look at an en-vogue idea in oncology, an awkward welcome for a new CEO, and a twist on the classic drug pricing backlash.
